The FDA has informed Abbvie that their supplemental application for new indications (PsA and AS) for upadacitinib (Rinvoq) has been delayed; the FDA citing its ongoing review of tofacitinibs safety concerns stemming from the ORAL Surveillance RA study https://t.co/sSJyVtQNYu